Page 483 - Binder2

(pg. 42) Prakash, S., Malhotra, M., Rathi, R., & Ahmad, S.
(2011). Targeted mucosal delivery of biologics using
nanocarriers and oral vaccines. Expert Opinion on Drug
Delivery, 8(6), 761–777.
https://doi.org/10.1517/17425247.2011.568936

(pg. 183) Ma, J. K., Drake, P. M., & Christou, P. (2003).
The production of recombinant pharmaceutical proteins in
plants. Nature Reviews Genetics, 4(10), 794–805.

(pg. 210) Tusé, D., Nandi, S., McDonald, K. A., & Buyel,
J. F. (2020). The emergency response capacity of plant-
based biopharmaceutical manufacturing-What it is and
what it could be. Frontiers in Plant Science, 11, 594019.

(pg. 184) Stöger, E., Ma, J. K., Fischer, R., & Christou, P.
(2005). Sowing the seeds of success: pharmaceutical
proteins from plants. Current Opinion in Biotechnology,
16(2), 167–173.

(pg. 410) Paul, M., & Ma, J. K. (2011). Plant-made
pharmaceuticals: leading products and production
platforms. Biotechnology and Applied Biochemistry, 58(1),
58–67.

(pg. 195) Pilot trial of plant-made IgA for enteric
infections. (2023). Travel Medicine & Infectious Disease
Journal, [DOI TBD].

(pg. 151) COUR Therapeutics. (2024). Platform overview
and pipeline highlights. Investor Briefing.

(pg. 57) U.S. Food & Drug Administration. (2023).
Guidance for Industry: Plant-Derived Pharmaceuticals.

481